Gefitinib for asymptomatic brain metastasis from advanced non‐small cell lung cancer: Report of a favourable outcome

Brain metastasis (BM) is common in patients with non‐small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now been included as standard treatment options for NSCLC harboring EGFR‐activating mutations, only a few prospective reports d...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wen‐Yang, Liu, Yu‐Tao, Yang, Lin, Zhang, Ye, Liu, Peng, Wang, Yan, Hui, Zhou‐Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930972/
https://www.ncbi.nlm.nih.gov/pubmed/27385995
http://dx.doi.org/10.1111/1759-7714.12335
Descripción
Sumario:Brain metastasis (BM) is common in patients with non‐small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now been included as standard treatment options for NSCLC harboring EGFR‐activating mutations, only a few prospective reports demonstrate the efficacy of these agents in a BM setting. We report a case of a patient with advanced NSCLC, in which oral gefitinib documented a significant antitumor effect on parallel progression of extracranial lesion and BM occurred during chemotherapy.

Ejemplares similares